V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320005575 | 320005789 | 1.65 | 78 | Neo-adjuvant (N) | 2016-03-09 | 2016-03-09 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 320022750 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320005576 | 320003919 | 1.46 | 79.5 | Palliative (P) | 2014-07-10 | 2014-08-01 | OCTOPUS Trial | N | N | 320022758 | CETUXIMAB + RT |
| 320005577 | 320003921 | 1.85 | 54 | Palliative (P) | 2018-05-13 | 2018-05-18 | EOX | N | N | 320022766 | CARBOPLATIN + RT |
| 320005578 | 320003921 | 1.86 | null | Adjuvant (A) | 2017-05-27 | 2017-06-03 | Cisplatin + Docetaxel +Fluorouracil | 01 | N | 320022766 | CARBOPLATIN + VINCRISTINE |
| 320005579 | 320003923 | 1.77 | 75 | Palliative (P) | 2013-07-07 | 2013-07-08 | Cetuximab+Cisplatin+FU (> Cycle 2) | 02 | N | 320022776 | FLUOROURACIL + MITOMYCIN + RT |
| 320005580 | 320003925 | 1.64 | 50 | Adjuvant (A) | 2014-05-06 | 2014-08-05 | ETOPOSIDE | N | N | 320022802 | CISPLATIN + GEMCITABINE |
| 320005581 | 320005794 | 1.7 | 80 | Neo-adjuvant (N) | 2018-06-14 | 2018-12-03 | Pemetrexed | N | N | 320022811 | IMATINIB |
| 320005582 | 320003929 | 1.83 | 67 | Adjuvant (A) | 2017-07-16 | 2017-07-24 | Carboplatin + Etoposide IV 3 day | N | N | 320022821 | CARBO + FLUOROURACIL |
| 320005583 | 320003931 | 1.66 | 83 | Palliative (P) | 2013-10-03 | 2014-06-19 | BEVACIZUMAB + CARBO + PACLITAXEL | 2 | Y | 320022821 | DOXORUBICIN + IFOSFAMIDE |
| 320005584 | 320003931 | 1.82 | 83.9 | Palliative (P) | 2018-07-08 | 2018-07-15 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 320022821 | IMATINIB |
| 320005585 | 320003932 | 1.68 | 80.6 | Curative (C) | 2015-12-19 | 2015-12-19 | AFLIBERCEPT + FU + IRINOTECAN | N | N | 320022832 | POUT TRIAL |
| 320005586 | 320005798 | 1.58 | null | null | null | 2013-11-04 | POUT TRIAL | null | null | 320022835 | NIVOLUMAB |
| 320005587 | 320003934 | 1.57 | null | Palliative (P) | 2016-06-13 | 2016-06-15 | HCX (Cape + Cisp + Tras) - Main | 02 | N | 320022850 | PEMBROLIZUMAB |
| 320005588 | 320005799 | 1.79 | 33.6 | Palliative (P) | 2014-11-27 | 2014-11-27 | PEMBROLIZUMAB | 02 | N | 320022860 | AFLIBERCEPT + FU + IRINOTECAN |
| 320005589 | 320003935 | null | 85 | Palliative (P) | 2013-07-30 | 2013-08-07 | Carboplatin + Cetux + FU (>Cycle 2) | 2 | N | 320022860 | CARBOPLATIN + RT |
| 320005590 | 320003937 | null | 51.1 | Adjuvant (A) | 2017-08-19 | 2017-09-03 | IVA | N | N | 320022868 | CETUXIMAB + CISPLATIN + FU |
| 320005591 | 320003939 | 1.73 | 71.8 | Adjuvant (A) | null | 2015-10-04 | Carboplatin + Cetux + FU (>Cycle 2) | null | null | 320022881 | PEMBROLIZUMAB |
| 320005592 | 320003941 | 1.59 | 80 | Palliative (P) | 2017-11-29 | 2017-12-20 | PEMBROLIZUMAB | 02 | N | 320022894 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320005593 | 320003942 | null | 74.4 | Palliative (P) | 2012-01-28 | 2013-07-08 | CARBO + FLUOROURACIL | N | null | 320022895 | CISPLATIN + FLUOROURACIL + RT |
| 320005594 | 320005803 | 1.87 | 77.4 | Neo-adjuvant (N) | 2016-09-16 | 2016-10-03 | Carboplatin + Etoposide IV 3 day | N | N | 320022903 | CARBOPLATIN + RT |
| 320005595 | 320005803 | 1.56 | 80 | Palliative (P) | 2016-05-02 | 2016-05-19 | Docetaxel | N | N | 320022903 | TRABECTEDIN |
| 320005596 | 320005803 | 1.59 | 35.45 | Palliative (P) | 2016-10-31 | 2016-11-10 | Bevacizumab+Carbo+Gemcitabine | null | null | 320022903 | NAB-PACLITAXEL |
| 320005600 | 320003944 | 1.81 | 91.5 | Palliative (P) | 2018-01-08 | 2018-01-09 | Ipilimumab | N | N | 320022984 | DOCETAXEL |
| 320005601 | 320003945 | 1.7 | 57.4 | Curative (C) | 2017-04-16 | 2017-04-18 | Irinotecan + Modified De Gramont | N | N | 320022984 | BEVACIZUMAB + CARBO |
| 320005602 | 320003946 | null | 29.1 | Palliative (P) | 2015-05-23 | 2015-06-16 | Paclitaxel+Trastuzumab 21 day Maint | N | N | 320022990 | CARBOPLATIN + RT |
| 320005603 | 320003947 | 1.53 | 64.6 | Adjuvant (A) | 2014-08-15 | 2014-08-20 | Docetaxel | N | N | 320023007 | BCG |
| 320005604 | 320003949 | 1.73 | null | Curative (C) | 2014-02-06 | 2014-02-13 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | 320023009 | TRABECTEDIN |
| 320005605 | 320003949 | 1.94 | null | Neo-adjuvant (N) | 2015-02-26 | 2015-02-26 | Carbo F | Y | N | 320023009 | GEMCITABINE |
| 320005606 | 320003949 | 1.67 | 99.2 | Curative (C) | 2016-07-16 | 2016-11-05 | PEMBROLIZUMAB | N | N | 320023009 | GEMCITABINE |
| 320005607 | 320003950 | null | null | Palliative (P) | 2018-04-28 | 2018-06-12 | Carboplatin + Cetux + FU (>Cycle 2) | N | null | 320023057 | ETOPOSIDE |
| 320005608 | 320003951 | null | 76 | Neo-adjuvant (N) | 2016-12-25 | 2017-01-22 | POUT TRIAL | 2 | N | 320023057 | IVADO |
| 320005609 | 320003953 | 1.6 | 108.6 | Palliative (P) | 2018-02-10 | 2018-02-20 | NIVOLUMAB | N | N | 320023087 | BORTEZOMIB |
| 320005610 | 320003953 | 1.76 | 58.4 | Palliative (P) | null | 2017-06-22 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 320023087 | BORTEZOMIB |
| 320005611 | 320003954 | 1.62 | 65 | Disease modification (D) | 2013-12-27 | 2014-01-03 | EW EuroEwing 99 : VActI | 02 | N | 320023097 | AFLIBERCEPT + FU + IRINOTECAN |
| 320005612 | 320003954 | 1.61 | null | Palliative (P) | null | 2015-06-14 | ICON8 TRIAL | null | null | 320023097 | ICON8B TRIAL |
| 320005613 | 320003955 | 1.71 | 74 | Curative (C) | 2017-07-05 | 2017-10-07 | TCF | 02 | N | 320023106 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005614 | 320003955 | null | 51.4 | null | 2016-08-23 | 2016-09-07 | Niraparib | N | N | 320023106 | ICON8B TRIAL |
| 320005615 | 320003956 | null | 78.4 | Neo-adjuvant (N) | null | 2018-01-28 | NIVOLUMAB | null | null | 320023121 | PEMBROLIZUMAB |
| 320005617 | 320003957 | 1.53 | 60.6 | Palliative (P) | 2015-09-01 | 2015-09-01 | GEMCITABINE + TIP | 2 | N | 320023133 | POMB/ACE |
| 320005618 | 320005814 | 1.54 | 87 | Palliative (P) | 2013-08-04 | 2013-08-19 | AXI-STS TRIAL | N | N | 320023140 | GEMCITABINE + TIP |
| 320005619 | 320003962 | null | 64.6 | Palliative (P) | 2015-03-10 | 2015-04-03 | Y-90 | 02 | N | 320023140 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320005620 | 320003964 | 1.71 | 34 | Palliative (P) | 2015-10-23 | 2015-10-30 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | 320023154 | PEMBROLIZUMAB |
| 320005621 | 320003964 | 1.73 | 79.9 | Curative (C) | 2015-04-17 | 2015-04-17 | Mitomycin Intravesical | 2 | N | 320023154 | TEMOZOLOMIDE |
| 320005622 | 320003965 | 1.59 | 0 | Adjuvant (A) | 2016-11-29 | 2016-11-30 | Niraparib | 2 | N | 320023162 | CISPLATIN + GEMCITABINE |
| 320005623 | 320005818 | 1.56 | 51.4 | Palliative (P) | 2018-06-19 | 2018-06-19 | Docetaxel 75mg/m2 (21 day) | 2 | Y | 320023192 | EOX |
| 320005624 | 320003970 | 1.72 | 84.4 | Palliative (P) | 2017-03-25 | 2017-03-25 | Capecitabine + Oxaliplatin 21day | 02 | N | 320023192 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005625 | 320003972 | 1.7 | 121.6 | Palliative (P) | 2017-02-15 | 2017-04-02 | NIVOLUMAB | N | N | 320023196 | CETUXIMAB + CISPLATIN + FU |
| 320005626 | 320003973 | null | 76.4 | Palliative (P) | 2015-01-03 | 2015-01-11 | Niraparib | N | N | 320023207 | ICON TRIAL |
| 320005627 | 320005820 | 1.57 | null | Curative (C) | 2018-03-01 | 2018-03-02 | ETOPOSIDE | 2 | N | 320023216 | GEMCITABINE |
| 320005628 | 320003975 | 1.81 | 90 | Palliative (P) | 2018-08-10 | 2019-01-04 | CISPLATIN + ETOPOSIDE | N | N | 320023226 | PEMETREXED |